Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNUS-2 phase 3 study of ianalumab in active Sjogren's syndrome
jRCT2041220098Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in Sjögren's syndrome (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in EULAR Sjogren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo. Started Nov 2022; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2041220098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220098.